News
OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease,...
globenewswire.ca
... treat these diseases, but which may have limited efficacy," said Jai Balkissoon, MD, FACS, Vice President Clinical Development, OXiGENE.
Print - OXiGENE Announces Presentation of Encouraging OXi
www.globenewswire.com
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
Stockwatch
www.stockwatch.com
No Hype - just the Facts. Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
OXiGENE achieves interim safety objective from phase II ovarian...
pharmabiz.com
OXiGENE achieves interim safety objective from phase II ovarian cancer trial of Zybrestat plus bevacizumab
sorted by relevance / date